SAMUEL ETCHIE: Open Payments
NPI 1124039052 · LA MESA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$22,372 in 90 payments from 12 companies in 2025. Trend: 2023 $1,848 · 2024 $22,858 · 2025 $22,372
Speaker / faculty: $17,499Food & beverage: $3,693Travel & lodging: $991Education: $189
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 25 | $19,406 |
| Alkermes, Inc. | 18 | $871 |
| E.R. Squibb & Sons, L.L.C. | 25 | $453 |
| Neurocrine BioSciences, Inc. | 3 | $331 |
| Vanda Pharmaceuticals Inc. | 4 | $307 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $288 |
| Axsome Therapeutics, Inc. | 2 | $228 |
| Otsuka America Pharmaceutical, Inc. | 3 | $181 |
| Janssen Pharmaceuticals, Inc | 1 | $145 |
| ACADIA Pharmaceuticals Inc | 1 | $114 |
Products named: UZEDY, ARISTADA, COBENFY, LYBALVI, INGREZZA, FANAPT, CAPLYTA, Auvelity.
Industry payments across CA — which companies pay providers there.
